Photo of Abram Shanedling

Abram Shanedling is an associate in the Business Trial Practice Group in the firm's Washington, D.C. office and a member of the firm’s Telecom Team.

Earlier this week, a Second Circuit panel resolved a sharp disagreement among district courts regarding the interpretation of the forum defendant rule in the context of a multi-district litigation (“MDL”) involving dozens of product liability lawsuits against the makers of the blood-thinning medication Eliquis.

In Gibbons v. Bristol-Myers Squibb Co., ___ F.3d ___, 2019 WL 1339013 (2d Cir. March 26, 2019), the court unanimously affirmed the district court’s holding that 33 cases were properly removed to federal court and that the claims were impliedly preempted by FDA labeling rules.
Continue Reading Second Circuit Affirms “Snap” Removal Practice